- Medicine Access and Rational Use > Better Medicines for Children
- Medicine Access and Rational Use > Selection
(2001; 25 pages) [French]
1. WHO. New data on the prevention of mother-to-child transmission of HIV and their policy implications: conclusions and recommendations. October 2000. Available at http://www.who.int/reproductive-health/RTIs. Accessed March 8, 2001.
2. Boehringer Ingelheim offers Viramune® (nevirapine) free of charge to developing economies for the prevention of HIV-1 mother-to-child transmission. 7 July 2000. Available at http://www.boehringer-ingelheim.com/corporate/home. Accessed October 26, 2000.
3. UNAIDS/WHO. AIDS epidemic update: December 2000. UNAIDS/00.44E - WHO/CDS/CSR/EDC/2000.9.
4. Dabis F, Msellati P, Dunn D, et al. Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues Ghent (Belgium),17-20 February 1992. The Working Group on Mother-to-Child Transmission of HIV. AIDS. 1993; 7(8):1139-48.
5. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000; 283(9):1175-1182.
6. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994; 331(18):1173-1180.
7. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS. 1998; 12(2):205-10.
8. Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA. 1998; 280(1):55-60.
9. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R. Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acq Immune Defic Syndr. 2000; 24:45-47.
10. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999; 53:773-780.
11. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 1999; 353:786-792.
12. Wiktor SZ, Ekpini E, Karon JM, et al. Short course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d’Ivoire: a randomised trial. Lancet. 1999; 353:781-785.
13. Gray G. Early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1, Abstract LbOr5, 13th International AIDS Conference, Durban, South Africa, 9-14 July 2000.
14. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
15. Wiktor SZ, Leroy V, Ekpini ER, et al. 24-month efficacy of short-course maternal zidovudine for the prevention of mother-to-child HIV-1 transmission in a breast feeding population: A pooled analysis of two randomized clinical trials in West Africa, Abstract TuOrB354, 13th International AIDS Conference, Durban, South Africa, 9-14 July 2000.
16. Owor M, Deseyve M, Duefield C, et al. The one year safety and efficacy data of the HIVNET 012 trial. Abstract LbOr1, 13th International AIDS Conference Durban, South Africa, 9-14 July 2000.
17. Lallemant M, Jourdain G, LeCoeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med. 2000; 343(14):982-991.
18. Moodley D, on behalf of the SAINT Investigators Team. The SAINT trial: Nevirapine (NVP) versus zidovudine (ZVD) + lamivudine (3TC) in prevention of peripartum HIV transmission. Abstract LbOr 2, 13th International AIDS Conference 2000, Durban, South Africa.
19. Bardsley-Elliot A and Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatric Drugs. 2000;2(5):373-407.
20. Dorenbaum A. for the PACTG 316 Study Team. Report of results of PACTG 316: An international phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission. Abstract LB7, 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, USA.
21. Jackson JB, Mracna M, Guay L, et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-012).Abstract LbOr 13, 13th International AIDS Conference 2000, Durban, South Africa.
22. Cunningham CK, Britto P, Gelber R, et al. Genotype resistance analysis in women participating in PACTG 316 with HIV-1 RNA >400 copies/ml. Abstract 712, 8th Conference on Retroviruses and Opportunistic Infections 2001, Chicago, USA.
23. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1. JAMA. 2001; 285(16); 2083-2093.
24. WHO. Essential drugs: WHO model list (revised December 1999).WHO Drug Information. 1999; 13(4):249-262.
25. WHO. Safe and effective use of antiretroviral treatment in adults with particular references to resource limited countries (Revised edition).WHO/HSI/2000.04.
26. Pollard RB et al. Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20:1071-1092.
27. CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR. 2001;49(51):1153-1156.
28. WHO. Interagency guidelines: guidelines for drug donations (Revised edition). WHO/EDM/PAR/99.4. Available at http://www.who.int/medicines.
29. WHO. Interagency Pharmaceutical Coordination Group. Draft interagency statement: “Guidelines for accepting or endorsing preferential prices or donations of single-source pharmaceuticals”. WHO/EDM. December 2000.
30. WHO. Guidelines on interaction with commercial enterprises to achieve health outcomes (Annex to Guidelines on working with the private sector to achieve health outcomes); EB107/20;30 November 2000. Available at http://www.who.int/wha-1998/EBWHA/PDF/EB107/ee20.pdf.
31. WHO. 31st Report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations, Annex 6: Guiding Principles for Small Drug Regulatory Authorities. WHO. 1990.
32. WHO. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for drug regulatory authorities. WHO/DMP/RGS/98.5.
33. WHO. WHO Policy Perspective on Medicines: Globalization, TRIPS and Access to Pharmaceuticals. No. 3. March 2001. WHO Geneva. Available at http://www.who.int/medicines/
34. UNAIDS/UNICEF/WHO/MSF. Prices and Sources of Selected Drugs and Diagnostics for People Living with HIV/AIDS. Joint UNAIDS-UNICEF-WHO/HTP-MSF Project, May 2001. Available at http://www.who.int/medicines/.
For orders, contact:
World Health Organization
Family and Community Health Cluster
Department of HIV/AIDS
20 Avenue Appia, CH-1211 Geneva 27, Switzerland
Phone: +41 22 791 2111
Direct fax: +41 22 791 4834